Patents by Inventor Rebecca Weimer

Rebecca Weimer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • POLYOXAZOLINE-LIPID CONJUGATES AND LIPID NANOPARTICLES AND PHARMACEUTICAL COMPOSITIONS INCLUDING SAME
    Publication number: 20240108750
    Abstract: POZ-lipid conjugates and lipid nanoparticles (LNPs) including POZ-lipid conjugates used to facilitate delivery of an encapsulated payload. LNPs including POZ-lipid conjugates and a nucleic acid payload such as, but not limited to, mRNA or modified mRNA are disclosed. Such LNPs have no immunogenicity or reduced immunogenicity as compared to a corresponding LNP containing a PEG-lipid.
    Type: Application
    Filed: November 7, 2023
    Publication date: April 4, 2024
    Applicant: Serina Therapeutics, Inc.
    Inventors: J Milton Harris, Michael Bentley, Tacey Viegas, Randall Moreadith, Robert J Sharpe, Kunsang Yoon, Zhihao Fang, Rebecca Weimer
  • Subcutaneous delivery of polymer conjugates of therapeutic agents
    Patent number: 11944618
    Abstract: The present disclosure provides polymer conjugates comprising a polymer and an agent the agent linked to the polymer via a linking group containing a cleavable moiety.
    Type: Grant
    Filed: April 11, 2022
    Date of Patent: April 2, 2024
    Assignee: Serina Therapeutics, Inc.
    Inventors: Randall Moreadith, Kunsang Yoon, Zhihao Fang, Rebecca Weimer, Bekir Dizman, Tacey Viegas, Michael David Bentley
  • CLEAVABLE CONJUGATES OF CATECHOL COMPOUNDS AND WATER-SOLUBLE POLYMERS AND METHODS OF TREATMENT USING THE SAME
    Publication number: 20240016798
    Abstract: Described are conjugates comprising a water-soluble polymer linked to a compound comprising a catechol moiety via a cleavable linkage, wherein the cleavable linkage is formed between the water-soluble polymer and a first phenolic hydroxyl group of the catechol moiety and a second phenolic hydroxyl group of the catechol moiety is linked to a blocking group wherein the rate of hydrolytic release of the compound comprising the catechol moiety is controlled, at least in part, through structure or design of the blocking group on the second phenolic hydroxyl group of the catechol moiety. Therefore, the rate of hydrolytic release of the compound comprising the catechol moiety can be tuned through structural design of the group on the second phenolic hydroxyl group of the catechol moiety. Compounds used in the synthesis of the described conjugates and methods of using the described conjugate and other compounds in the treatment of dopamine-responsive disorders are also described.
    Type: Application
    Filed: September 19, 2023
    Publication date: January 18, 2024
    Applicant: Serina Therapeutics, Inc.
    Inventors: Michael Bentley, Zhihao Fang, Rebecca Weimer, Tacey Viegas, Randall Moreadith
  • Cleavable conjugates of catechol compounds and water-soluble polymers and methods of treatment using the same
    Patent number: 11766432
    Abstract: Described are conjugates comprising a water-soluble polymer linked to a compound comprising a catechol moiety via a cleavable linkage, wherein the cleavable linkage is formed between the water-soluble polymer and a first phenolic hydroxyl group of the catechol moiety and a second phenolic hydroxyl group of the catechol moiety is linked to a blocking group wherein the rate of hydrolytic release of the compound comprising the catechol moiety is controlled, at least in part, through structure or design of the blocking group on the second phenolic hydroxyl group of the catechol moiety. Therefore, the rate of hydrolytic release of the compound comprising the catechol moiety can be tuned through structural design of the group on the second phenolic hydroxyl group of the catechol moiety. Compounds used in the synthesis of the described conjugates and methods of using the described conjugate and other compounds in the treatment of dopamine-responsive disorders are also described.
    Type: Grant
    Filed: July 27, 2019
    Date of Patent: September 26, 2023
    Assignee: Serina Therapeutics, Inc.
    Inventors: Michael Bentley, Zhihao Fang, Rebecca Weimer, Tacey Viegas, Randall Moreadith
  • POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIES
    Publication number: 20230009076
    Abstract: The present disclosure provides for polyoxazoline (POZ) conjugates wherein the conformation of the POZ conjugate and the release rate of an agent from the POZ conjugate can be controlled by selecting one or more characteristics of the POZ polymer. Methods of controlling the conformation of a POZ conjugate and the release rate of an agent prior are provided as well as methods of treatment using such POZ conjugates and methods. Pharmaceutical compositions comprising a POZ conjugate are also provided.
    Type: Application
    Filed: June 28, 2020
    Publication date: January 12, 2023
    Applicant: SERINA THERAPEUTICS, INC.
    Inventors: J Milton HARRIS, Michael D BENTLEY, Tacey X VIEGAS, Randall W MOREADITH, Zhihao FANG, Kunsang YOON, Rebecca WEIMER
  • SUBCUTANEOUS DELIVERY OF POLYMER CONJUGATES OF THERAPEUTIC AGENTS
    Publication number: 20220354841
    Abstract: The present disclosure provides polymer conjugates comprising a polymer and an agent, the agent linked to the polymer via a linking group containing a cleavable moiety.
    Type: Application
    Filed: April 11, 2022
    Publication date: November 10, 2022
    Applicant: Serina Therapeutics, Inc.
    Inventors: Randall Moreadith, Kunsang Yoon, Zhihao Fang, Rebecca Weimer, Bekir Dizman, Tacey Viegas, Michael David Bentley
  • POLYOXAZOLINE-LIPID CONJUGATES AND LIPID NANOPARTICLES AND PHARMACEUTICAL COMPOSITIONS INCLUDING SAME
    Publication number: 20220249695
    Abstract: POZ-lipid conjugates and lipid nanoparticles (LNPs) including POZ-lipid conjugates used to facilitate delivery of an encapsulated payload. LNPs including POZ-lipid conjugates and a nucleic acid payload such as, but not limited to, mRNA or modified mRNA are disclosed. Such LNPs have no immunogenicity or reduced immunogenicity as compared to a corresponding LNP containing a PEG-lipid.
    Type: Application
    Filed: February 4, 2022
    Publication date: August 11, 2022
    Applicant: Serina Therapeutics, Inc.
    Inventors: J Milton HARRIS, Michael Bentley, Tacey Viegas, Randall Moreadith, Robert J. Sharpe, Kunsang Yoon, Zhihao Fang, Rebecca Weimer
  • Subcutaneous delivery of polymer conjugates of therapeutics agents
    Patent number: 11298350
    Abstract: The present disclosure provides polymer conjugates comprising a polymer and an agent, the agent linked to the polymer via a linking group containing a cleavable moiety.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: April 12, 2022
    Assignee: Serina Therapeutics, Inc.
    Inventors: Randall Moreadith, Kunsang Yoon, Zhihao Fang, Rebecca Weimer, Bekir Dizman, Tacey Viegas, Michael David Bentley
  • Subcutaneous delivery of poly(oxazoline) polymer conjugates
    Patent number: 11224595
    Abstract: The present disclosure provides polymer conjugates comprising a polymer and an agent, the agent linked to the polymer via a linking group containing a hydrolyzable moiety.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: January 18, 2022
    Assignee: Serina Therapeutics, Inc.
    Inventors: Randall Moreadith, Michael Bentley, Kunsang Yoon, Zhihao Fang, Rebecca Weimer, Bekir Dizman, Tacey Viegas
  • Cleavable Conjugates of Catechol Compounds and Water-Soluble Polymers and Methods of Treatment Using the Same
    Publication number: 20210186957
    Abstract: Described are conjugates comprising a water-soluble polymer linked to a compound comprising a catechol moiety via a cleavable linkage, wherein the cleavable linkage is formed between the water-soluble polymer and a first phenolic hydroxyl group e of the catechol moiety and a second phenolic hydroxyl group of the catechol moiety is linked to a blocking group wherein the rate of hydrolytic release of the compound comprising the catechol moiety is controlled, at least in part, through structure or design of the blocking group on the second phenolic hydroxyl group of the catechol moiety. Therefore, the rate of hydrolytic release of the compound comprising the catechol moiety can be tuned through structural design of the group on the second phenolic hydroxyl group of the catechol moiety. Compounds used in the synthesis of the described conjugates and methods of using the described conjugate and other compounds in the treatment of dopamine-responsive disorders are also described.
    Type: Application
    Filed: July 27, 2019
    Publication date: June 24, 2021
    Inventors: Michael BENTLEY, Zhihao FANG, Rebecca WEIMER, Tacey VIEGAS, Randall MOREADITH
  • SUBCUTANEOUS DELIVERY OF POLYMER CONJUGATES OF THERAPEUTICS AGENTS
    Publication number: 20200093816
    Abstract: The present disclosure provides polymer conjugates comprising a polymer and an agent, the agent linked to the polymer via a linking group containing a cleavable moiety.
    Type: Application
    Filed: September 30, 2019
    Publication date: March 26, 2020
    Inventors: Randall Moreadith, Kunsang Yoon, Zhihao Fang, Rebecca Weimer, Bekir Dizman, Tacey Viegas, Michael David Bentley
  • Subcutaneous delivery of polymer conjugates of therapeutic agents
    Patent number: 10426768
    Abstract: The present disclosure provides polymer conjugates comprising a polymer and an agent, the agent linked to the polymer via a linking group containing a cleavable moiety.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: October 1, 2019
    Assignee: Sarina Therapeutics, Inc.
    Inventors: Randall Moreadith, Kunsang Yoon, Zhihao Fang, Rebecca Weimer, Bekir Dizman, Tacey Viegas, Michael David Bentley
  • SUBCUTANEOUS DELIVERY OF POLY(OXAZOLINE) POLYMER CONJUGATES
    Publication number: 20190290638
    Abstract: The present disclosure provides polymer conjugates comprising a polymer and an agent, the agent linked to the polymer via a linking group containing a hydrolyzable moiety.
    Type: Application
    Filed: June 10, 2019
    Publication date: September 26, 2019
    Inventors: Randall MOREADITH, Michael BENTLEY, Kunsang YOON, Zhihao FANG, Rebecca WEIMER, Bekir DIZMAN, Tacey VIEGAS
  • Subcutaneous delivery of poly(oxazoline) polymer conjugates
    Patent number: 10314837
    Abstract: The present disclosure provides polymer conjugates comprising a polymer and an agent, the agent linked to the polymer via a linking group containing a hydrolyzable moiety.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: June 11, 2019
    Assignee: Serina Therapeutics, Inc.
    Inventors: Randall Moreadith, Michael David Bentley, Kunsang Yoon, Zhihao Fang, Rebecca Weimer, Bekir Dizman, Tacey Viegas
  • SUBCUTANEOUS DELIVERY OF POLYMER CONJUGATES OF THERAPEUTIC AGENTS
    Publication number: 20170202972
    Abstract: The present disclosure provides polymer conjugates comprising a polymer and an agent, the agent linked to the polymer via a linking group containing a cleavable moiety.
    Type: Application
    Filed: April 5, 2017
    Publication date: July 20, 2017
    Inventors: Randall MOREADITH, Kunsang Yoon, Zhihao Fang, Rebecca Weimer, Bekir Dizman, Tacey Viegas, Michael David Bentley
  • Subcutaneous Delivery of Poly(oxazoline) Polymer Conjugates
    Publication number: 20160303250
    Abstract: The present disclosure provides polymer conjugates comprising a polymer and an agent, the agent linked to the polymer via a linking group containing a hydrolyzable moiety.
    Type: Application
    Filed: June 29, 2016
    Publication date: October 20, 2016
    Inventors: Randall MOREADITH, Michael David BENTLEY, Kunsang YOON, Zhihao FANG, Rebecca WEIMER, Bekir DIZMAN, Tacey VIEGAS
  • SUBCUTANEOUS DELIVERY OF POLYMER CONJUGATES OF THERAPEUTIC AGENTS
    Publication number: 20140271527
    Abstract: The present disclosure provides polymer conjugates comprising a polymer and an agent, the agent linked to the polymer via a linking group containing a cleavable moiety.
    Type: Application
    Filed: November 1, 2012
    Publication date: September 18, 2014
    Applicant: Serina Therapeutics, Inc.
    Inventors: Randall Moreadith, Kunsang Yoon, Zhihao Fang, Rebecca Weimer, Bekir Dizman, Tacey Viegas, Michael David Bentley
  • Subcutaneous delivery of poly(oxazoline) conjugates
    Patent number: 8597633
    Abstract: The present disclosure provides polymer conjugates comprising a polymer and an agent, the agent linked to the polymer via a linking group containing a hydrolyzable moiety.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: December 3, 2013
    Assignee: Serina Therapeutics, inc.
    Inventors: Randall Moreadith, Michael David Bentley, Kunsang Yoon, Zhihao Fang, Rebecca Weimer, Bekir Dizman, Tacey Viegas
  • Subcutaneous delivery of poly(oxazoline) conjugates
    Patent number: 8383093
    Abstract: The present disclosure provides polymer conjugates comprising a polymer and an agent, the agent linked to the polymer via a linking group containing a hydrolyzable moiety.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: February 26, 2013
    Assignee: Serina Therapeutics, Inc.
    Inventors: Randall Moreadith, Michael David Bentley, Kunsang Yoon, Zhihao Fang, Rebecca Weimer, Bekir Dizman, Tacey Viegas